Shed

About Shed

Shed entered the GLP-1 telehealth market in 2022 with one of the most distinctive value propositions we have reviewed: a 10% weight loss guarantee and unique medication formats including lozenges and liquid drops. The platform offers both brand-name medications (Wegovy and Zepbound) and compounded formulations, with monthly pricing between $199 and $499. The upper end of that range places Shed among the pricier options, but the weight loss guarantee and novel delivery methods add value that standard injectable-only providers do not offer.

Trust metrics are strong. Shed holds a 4.6 rating on Trustpilot across 830+ reviews, a score that reflects high patient satisfaction at a meaningful volume. The B BBB rating is solid, indicating responsible business practices and adequate complaint resolution. Together, these metrics place Shed in the high-trust category by our evaluation standards, a designation that carries weight in a market where many providers struggle with public perception.

The lozenge and liquid drop formulations are Shed’s most innovative feature. While the vast majority of GLP-1 telehealth providers offer only injectable semaglutide or tirzepatide, Shed provides compounded alternatives in formats that do not require needles. For the significant population of patients who experience needle anxiety, injection site reactions, or simply prefer oral administration, these alternative delivery methods remove a major barrier to treatment adherence. The lozenges dissolve sublingually, and the liquid drops offer precise dose control — both designed to maintain therapeutic efficacy while improving the patient experience.

The 10% body weight loss guarantee is a bold commitment that very few competitors are willing to make. While the specific terms and conditions of the guarantee should be reviewed carefully before enrollment, the willingness to stake business outcomes on clinical results signals confidence in the treatment protocols. This guarantee also aligns financial incentives between provider and patient in a way that fee-for-service models do not — Shed is motivated to ensure patients actually lose weight, not just maintain a subscription. The clinical support model is medium-tier with standard provider consultations and progress monitoring.

Shed’s main drawback is pricing. At 9-9/month, the platform is accessible at the low end but premium at the top. Patients opting for brand-name Wegovy or Zepbound through Shed will likely pay toward the upper range, while compounded lozenges and drops fall lower. The medium-support model also means patients do not receive the dietitian access or intensive coaching available at some competitors. However, for patients who specifically want non-injectable GLP-1 options or are motivated by the weight loss guarantee, Shed offers something genuinely unique in the current telehealth landscape.

At a Glance